Neurocrine Biosciences: Of The Original Report To Include The Audited Consolidated Financial Statements Of Soleno (as Defined In The Original Report) As Of And For The Year Ended December31, 2025 And To Include The Unaudited Interim Condensed Consolidated Financial Statements Of Soleno As Of And For The Three Months Ended March 31, 2026; And (ii)update The Information In Item 9.01(b) Of The Original Report To Include The Unaudited Pro Forma Condensed Combined Financial Information Of The Company, Consisting Of The Unaudited Pro Forma Condensed Combined Statements Of Income For The Six Months Ended June30, 2026 And The Year Ended December31, 2025. This Amendment No.1 Does Not Amend Any Other Item Of The Original Report Or Purport To Provide An Update Or A Discussion Of Any Developments At The Company Subsequent To The Filing Date Of The Original Report

Show full article

This functionality is available for registred users only

• Full name
  Neurocrine Biosciences, Inc.
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***